Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and Cetuximab in Advanced Malignancy
NCT02095054Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2014
- Primary completion
- Mar 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of regorafenib and cetuximab in solid tumor (advanced stage), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Mar 2014; status: completed.
02
Drugs
regorafenibcetuximab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02095054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02095054.